Login / Signup

Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment.

Aleksi M OlkkolaTuija TapaninenAleksi TornioMilka Hauta-AhoOuti Lapatto-ReiniluotoMikko NeuvonenJohanna I KiiskiPertti J NeuvonenMikko NiemiJanne T Backman
Published in: British journal of clinical pharmacology (2023)
Posaconazole increases ibrutinib exposure substantially, by about 10-fold. This interaction cannot be avoided by dosing the drugs 12 hours apart. In general, a 70 mg daily dose of ibrutinib should not be exceeded during posaconazole treatment, to avoid potentially toxic systemic ibrutinib concentrations.
Keyphrases
  • chronic lymphocytic leukemia
  • combination therapy
  • replacement therapy